Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAetna Enfuvirtide (Fuzeon) Coverage Prior Auth | O…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0671

    Enfuvirtide (Fuzeon)

    Customize your policy alerts

    Sign up for Aetna Policy 0671 alerts

    Get alerted when Policy 0671 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity criteria, dosing notes, experimental uses, and coding guidance for enfuvirtide (Fuzeon) injections for treatment-experienced patients with HIV-1; applies to Aetna benefit administration.

    Policy Summary
    PayerAetna
    PolicyEnfuvirtide (Fuzeon)
    Policy CodePolicy 0671
    Change TypeNo material change
    Effective DateSep 5, 2003
    Last ReviewMar 23, 2023
    Next Review DateJan 25, 2024
    Key ActionObtain prior authorization documenting treatment-experienced status with viremia or documented resistance/intolerance.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90 mg BIDrecommended adult dose
    108 mgvial strength
    98%injection site reactions
    3 momin prior therapy
    J1324HCPCS

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Enfuvirtide (Fuzeon)

    inv-01: Initial Approval — ANY of the following are met

    Aetna considers enfuvirtide medically necessary when ANY of the following are met:

    ANY of the following: The member has viremia despite 3 or more prior months of therapy with at least one appropriate regimen used to treat HIV>= 3 months prior therapy

    From policy criteria

    ANY of the following: The member has viremia and documented resistance or intolerance to at least one appropriate regimen used to treat HIVdocumented resistance or intolerance

    From policy criteria

    inv-02: Continuation of Therapy — ALL of the following are met

    Continuation of therapy is considered medically necessary when ALL of the following are met:

    ALL of the following: Member has had a positive or stable virologic response to enfuvirtidepositive or stable virologic response

    From policy continuation section

    Use of enfuvirtide (Fuzeon) for treatment‑naive HIV‑infected persons and for treatment of COVID‑19 is considered experimental and investigational (not covered). Aetna’s determination reflects that effectiveness for these indications has not been established.

    This Clinical Policy Bulletin is provided to assist in administering plan benefits and contains only a partial, general description of plan or program benefits; it does not constitute a contract or an offer of coverage. Treating providers remain responsible for medical advice and treatment. The bulletin may be updated and is subject to change.

    Indications for enfuvirtide outside the specified treatment‑experienced HIV‑1 population — for example, use in treatment‑naive persons or for management of COVID‑19 — are considered experimental/investigational and not medically necessary under this policy. Requests for such indications are at risk for denial; when coverage is being considered for HIV‑1, ensure the member meets the treatment‑experienced criteria and document the appropriate diagnosis code (B20) and supporting clinical information.

    Coding Guidance

    Covered HCPCS Codes if selection criteria are metHCPCSCovered
    J1324Injection, enfuvirtide, 1 mg
    Covered ICD-10 Codes if selection criteria are metICD-10Covered
    B20Human immunodeficiency virus [HIV] disease
    ICD-10 codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered
    U07.1COVID-19
    Pediatric dosing threshold and administration notes
    Pediatric weight threshold>= 11 kg for patients >= 6 years; dose 2 mg/kg twice daily up to a maximum of 90 mg twice daily (subcutaneous)
    Age minimum6 years of age and older
    Maximum pediatric dose90 mg twice daily (same as adult maximum)
    Administration routeSubcutaneous injection into upper arm, anterior thigh, or abdomen

    Provider Actions, Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization required. Requests must document that the member is treatment‑experienced with viremia despite prior therapy (≥3 months on at least one appropriate HIV regimen) or has viremia with documented resistance or intolerance to at least one appropriate HIV regimen. Include applicable billing code J1324 when submitting claims.

    • Prior authorization required showing treatment‑experienced status or documented resistance/intolerance
    • Billing code: J1324 (Injection, enfuvirtide, 1 mg)
    Note

    Prior Authorization: administrative details not specified

    The policy text does not specify additional prior authorization administrative details (such as submission portal, forms, or phone numbers). Consult the payer's provider resources or the Clinical Policy Bulletin Notes for administrative instructions.

    Background

    Enfuvirtide (Fuzeon) is an antiretroviral indicated for use in combination with other agents in treatment‑experienced patients with ongoing HIV‑1 replication despite therapy. It is supplied for injection and is billed using HCPCS J1324 (injection, enfuvirtide, 1 mg). Common adverse events include very frequent injection‑site reactions; pneumonia was reported more frequently in trials versus controls. Use outside the approved treatment‑experienced population (including treatment‑naive patients and COVID‑19) is considered experimental/investigational.

    Definitions

    Treatment‑experienced — definition and relation to FDA‑approved population
    Definition (treatment-experienced)Patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy (population for which Fuzeon is FDA‑approved)
    Clinical contextFuzeon is indicated in combination with other antiretroviral agents for treatment-experienced patients with ongoing viral replication despite therapy
    Implication for coveragePolicy applies to the FDA‑approved treatment‑experienced population; requests outside this population (e.g., treatment‑naive) are considered experimental/investigational
    Supporting evidenceRandomized studies (TORO‑1, TORO‑2) showed clinical benefit in treatment‑experienced patients
    Clinical Policy Bulletin — definition and disclaimer
    Definition (Clinical Policy Bulletin)
    Policy Summary
    PayerAetna
    PolicyEnfuvirtide (Fuzeon)
    Policy CodePolicy 0671
    Change TypeNo material change
    Effective DateSep 5, 2003
    Last ReviewMar 23, 2023
    Next Review DateJan 25, 2024
    Key ActionObtain prior authorization documenting treatment-experienced status with viremia or documented resistance/intolerance.
    SourceLink
    On This Page
    Coverage Criteria for Enfuvirtide (Fuzeon)Coding GuidanceProvider Actions, Prior Authorization and DocumentationBackgroundDefinitions
    Note

    No specific authorization/denial workflow provided

    No specific authorization or denial algorithm beyond the clinical criteria is provided in the referenced policy sections. Administrative review and usual medical‑necessity adjudication apply; requests not meeting the listed clinical criteria may be denied.

    • Requests not meeting the initial approval criteria (viremia despite ≥3 months therapy or documented resistance/intolerance) are subject to denial
    Documentation Required

    Required Supporting Clinical and Coding Documentation

    Supporting clinical documentation must demonstrate treatment‑experienced status or documented resistance/intolerance and current viremia (laboratory results, prior regimen history, resistance testing or documented intolerance). Include ICD‑10 code B20 when criteria are met; do not use U07.1 (COVID‑19) for coverage.

    • Clinical: viral load results showing viremia; prior antiretroviral treatment history (≥3 months on ≥1 appropriate regimen) or resistance test results; documentation of intolerance if applicable
    • Coding: ICD‑10 B20 for HIV disease when criteria met; J1324 for enfuvirtide; U07.1 (COVID‑19) is a not‑covered indication per policy
    Step Therapy

    Step therapy: not specified

    Step therapy is not specified in the provided policy text beyond the requirement that the member be treatment‑experienced or have documented resistance/intolerance. No sequential step‑therapy regimen or required trials are listed.

    Note

    No step therapy requirements or sequence specified

    There are no step‑therapy sequences or trials defined in the policy sections provided; the clinical criteria focus on treatment‑experienced status or documented resistance/intolerance rather than stepwise agent trials.

    An Aetna‑developed bulletin to assist in administering plan benefits; it is not an offer of coverage or medical advice
    ScopeProvides a partial, general description of plan or program benefits and may be updated; specific contract language and coverage determinations are governed by member documents
    Provider responsibilityTreating providers remain responsible for medical advice and treatment decisions; the bulletin is an administrative reference